Pharmaceutical intermediates are a kind of fine chemical products in the production process from pharmaceutical chemical raw materials to APIs or drugs, and are an important link
in the industrial chain of the pharmaceutical industry.
Pharmaceutical intermediates include antibacterial drug intermediates, antipyretic and analgesic drug intermediates, cardiovascular drug intermediates and anti-cancer pharmaceutical intermediates
.
The industry predicts that the size of China's pharmaceutical intermediates market will reach 227.
8 billion yuan
in 2022.
The industry pointed out that with the further refinement of the industrial structure adjustment and international division of labor of large multinational pharmaceutical companies, China has formed a complete pharmaceutical intermediate industry system from scientific research and development to production and sales, and it is expected that the scale of China's pharmaceutical intermediates market will reach 227.
8 billion yuan
in 2022.
Pharmaceutical intermediates industry is an important link in the industrial chain of the pharmaceutical industry, with the continuous improvement of the added value and process complexity of pharmaceutical intermediates in China, pharmaceutical intermediates are becoming a strong guarantee for the development of the pharmaceutical industry, and the degree of automation of pharmaceutical intermediates will continue to increase
.
For the improvement of the degree of automation of pharmaceutical intermediates, analysts said that with the continuous improvement of the national supporting system for safe production, the continuous rise in labor costs, and the increasingly stringent requirements of the pharmaceutical industry for the quality of intermediates, the production process of pharmaceutical intermediates is becoming more and more automated, which requires manufacturers to design automatic control schemes for the production characteristics of pharmaceutical intermediate products, and to select automatic control instruments and meters to continuously improve the degree of automation of
the production industry.
In addition, with the increasingly stringent requirements for energy conservation and environmental protection, as well as the complex manufacturing process of pharmaceutical intermediates and many reaction links, manufacturers in the industry should vigorously develop green advanced processes, develop environmental protection treatment facilities with standards and low-energy-saving production equipment, so as to implement the target responsibility of
reducing consumption and emissions.
For example, in recent years, the state has successively issued the "14th Five-Year" Pharmaceutical Industry Development Plan, the "14th Five-Year" National Pesticide Industry Development Plan, the "Comprehensive Directory of Environmental Protection (2021 Edition)", "Guiding Opinions on Promoting the Green Development of the API Industry", etc.
to promote the energy-saving and low-carbon development of the industry and improve the level of green manufacturing, which has become increasingly stringent
for energy conservation and environmental protection requirements of industry enterprises.
With the introduction of a series of policies, the concentration of pharmaceutical intermediates industry will be further improved, and those enterprises with backward technology and weak technology may gradually be eliminated
.
The allocation of market resources will also continue to gather
enterprises with strong comprehensive strength, energy saving and environmental protection technology.
It is reported that at present, the domestic pharmaceutical intermediate field has also ushered in a number of powerful enterprises
.
For example, Yaben Chemical is a high-end product customizer in the domestic pharmaceutical and pesticide intermediates industry, and has a certain position
in the domestic fine chemical industry.
According to the 2022 semi-annual performance report released by Yaben Chemical recently, the company's pharmaceutical intermediates business achieved operating income of 88.
58% year-on-year in the first half of the year, reaching 298 million yuan
.
The rapid large-scale development of the company's pharmaceutical intermediate products has also become a highlight
of the company's semi-annual report.
For example, Tuoxin Pharmaceutical is an enterprise integrating the research and development, production and sales of nucleoside (acid) APIs and pharmaceutical intermediates, and has strong strength
in the development and production of domestic nucleoside (acid) APIs and pharmaceutical intermediate products.
The company has the advantages of early start, large scale and full variety in the research and development field of domestic nucleoside (acid) APIs and pharmaceutical intermediates, and has formed a relatively complete product chain
from basic products to high-end products.
The company's 2022 semi-annual report shows that in the first half of the year, Tuoxin Pharmaceutical's nucleotides and nucleoside series products achieved revenue of about 115 million yuan and 0.
29 billion yuan respectively, accounting for 46.
56% and 11.
74%
of the total revenue, respectively.
Analysts said that the API and intermediate industry is in the middle of the pharmaceutical industry chain, with the pharmaceutical industry policy support, the aging trend of the population and the continuous enhancement of people's health awareness, the global API and intermediate industry will maintain sustained and steady growth
.
In recent years, the supply of domestic pharmaceutical APIs and intermediates is changing to quality, and it will be a definite trend
for domestic related enterprises to move to high-end characteristics, and the scale and profitability of patented APIs and intermediate products will be determined.
